• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

长效注射用卡替拉韦/利匹韦林在口服抗逆转录病毒治疗失败的小患者队列中有效。

Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy.

机构信息

Department of Medicine, Division of Infectious Diseases, University of Mississippi Medical Center . Jackson, Mississippi, USA.

出版信息

Clin Infect Dis. 2024 Jan 25;78(1):122-124. doi: 10.1093/cid/ciad511.

DOI:10.1093/cid/ciad511
PMID:37740255
Abstract

We report 12 patients with persistent viremia on oral antiretroviral therapy who were initiated on injectable cabotegravir/rilpivirine (iCAB/RPV) without oral lead-in. All patients achieved viral suppression without any virologic rebound. iCAB/RPV may be considered as an option for patients unable to maintain suppression on oral antiretroviral therapy.

摘要

我们报告了 12 例接受口服抗逆转录病毒治疗但持续病毒血症的患者，他们在没有口服先导药物的情况下开始接受注射用卡替拉韦/利匹韦林（iCAB/RPV）治疗。所有患者均实现了病毒抑制，无任何病毒学反弹。对于无法维持口服抗逆转录病毒治疗抑制的患者，iCAB/RPV 可被视为一种选择。

相似文献

1
Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy.长效注射用卡替拉韦/利匹韦林在口服抗逆转录病毒治疗失败的小患者队列中有效。
Clin Infect Dis. 2024 Jan 25;78(1):122-124. doi: 10.1093/cid/ciad511.
2
Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.每月注射用卡替拉韦/利匹韦林治疗成人 HIV 感染。
J Am Assoc Nurse Pract. 2022 Jul 1;34(7):918-923. doi: 10.1097/JXX.0000000000000729.
3
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.接受性和耐受性长效注射型卡替拉韦或利匹韦林在病毒学抑制的青少年艾滋病病毒感染者中的首个队列（IMPAACT 2017/MOCHA）：一项 1/2 期、多中心、开放性、非比较剂量发现研究的二次分析。
Lancet HIV. 2024 Apr;11(4):e222-e232. doi: 10.1016/S2352-3018(23)00301-6.
4
An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV.长效卡替拉韦+利匹韦林治疗病毒学抑制的 HIV 感染者的评价。
Expert Opin Pharmacother. 2022 Sep;23(13):1485-1495. doi: 10.1080/14656566.2022.2126310. Epub 2022 Sep 20.
5
Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population.抗逆转录病毒治疗初治和经治 HIV-1 感染人群中可能与卡替拉韦/利匹韦林失败相关的基因型因素的频率。
Infect Genet Evol. 2022 Oct;104:105358. doi: 10.1016/j.meegid.2022.105358. Epub 2022 Aug 31.
6
Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.长效卡替拉韦和利匹韦林每 8 周 1 次维持治疗与每日口服标准抗逆转录病毒治疗用于病毒学抑制的 HIV-1 感染者的 48 周疗效和安全性的间接比较。
BMC Infect Dis. 2022 May 4;22(1):428. doi: 10.1186/s12879-022-07243-3.
7
Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area.在纽约大都市区的基于医疗系统的诊所实施由药剂师主导的长效注射型卡替拉韦/利匹韦林方案治疗 HIV-1。
AIDS Patient Care STDS. 2024 Mar;38(3):115-122. doi: 10.1089/apc.2023.0250.
8
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.长效肌内注射卡替拉韦和利匹韦林治疗成人 HIV-1 感染（LATTE-2）：一项随机、开放标签、2b 期、非劣效性试验的 96 周结果。
Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.
9
The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.长效注射用卡替拉韦-利匹韦林在撒哈拉以南非洲治疗 HIV 的潜在作用：建模分析。
Lancet Glob Health. 2021 May;9(5):e620-e627. doi: 10.1016/S2214-109X(21)00025-5. Epub 2021 Mar 23.
10
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.简报：6 项正在进行的全球 IIb 期和 III 期临床试验中，COVID-19 对卡替拉韦/利匹韦林长效给药的影响。
J Acquir Immune Defic Syndr. 2022 Oct 1;91(2):157-161. doi: 10.1097/QAI.0000000000003031. Epub 2022 Jun 4.

引用本文的文献

1
Treatment experience of people living with HIV who transitioned from oral to long-acting injectable antiretrovirals in Puerto Rico: A qualitative study.波多黎各从口服抗逆转录病毒药物转换为长效注射用抗逆转录病毒药物的艾滋病毒感染者的治疗经历：一项定性研究。
PLoS One. 2025 Sep 15;20(9):e0332661. doi: 10.1371/journal.pone.0332661. eCollection 2025.
2
Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US.在美国，延迟对患有HIV且持续病毒血症的患者实施长效抗逆转录病毒疗法的临床后果。
Clin Infect Dis. 2025 Aug 4. doi: 10.1093/cid/ciaf428.
3
HIV Viral Suppression With Use of Long-Acting Antiretroviral Therapy in People With and Without Initial Viremia.
在有和没有初始病毒血症的人群中使用长效抗逆转录病毒疗法实现HIV病毒抑制
JAMA. 2025 Apr 22;333(16):1451-1453. doi: 10.1001/jama.2025.0109.
4
State-level variation in access to long-acting injectable antiretroviral therapy for HIV in the United States.美国各州在获取长效注射用抗逆转录病毒疗法治疗艾滋病方面的差异。
Health Aff Sch. 2025 Jan 29;3(2):qxaf016. doi: 10.1093/haschl/qxaf016. eCollection 2025 Feb.
5
Cost-effectiveness of long-acting cabotegravir/rilpivirine for people with HIV and adherence challenges at the Ward 86 clinic: an intermediate outcome analysis.长效卡博特韦/利匹韦林用于第86病房诊所面临依从性挑战的HIV感染者的成本效益：一项中间结局分析
AIDS. 2025 Jun 1;39(7):899-904. doi: 10.1097/QAD.0000000000004145. Epub 2025 Feb 4.
6
Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges.长效注射用卡博特韦/利匹韦林在有HIV且存在依从性挑战的人群中的应用。
Curr Opin HIV AIDS. 2025 Jan 1;20(1):11-18. doi: 10.1097/COH.0000000000000904. Epub 2024 Nov 8.
7
Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long-acting cabotegravir/rilpivirine among early adopters in three U.S. clinics.从首例开始学习：在美国三家诊所中，早期使用者对长效卡博特韦/利匹韦林的心理社会获益和治疗负担的定性研究。
J Int AIDS Soc. 2024 Nov;27(11):e26394. doi: 10.1002/jia2.26394.
8
Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial Viremia.初始病毒血症的HIV感染者开始使用长效卡博特韦/利匹韦林治疗48周时的病毒抑制率
Clin Infect Dis. 2025 Apr 30;80(4):864-870. doi: 10.1093/cid/ciae500.
9
Characterizing long-acting injectable antiretroviral therapy eligibility and initiation at a safety net academic medical center in the southeastern United States.在美国东南部一家安全网学术医疗中心对长效注射抗逆转录病毒疗法的适用性及启动情况进行特征分析。
Int J STD AIDS. 2025 Jan;36(1):47-55. doi: 10.1177/09564624241289998. Epub 2024 Oct 3.
10
Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system.患者与诊所工作人员对在城市安全网卫生系统中实施长效注射抗逆转录病毒治疗项目的看法。
Implement Sci Commun. 2024 Aug 29;5(1):93. doi: 10.1186/s43058-024-00631-7.